NCT02256033View on ClinicalTrials.gov

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Hepatic Impairment
Interventions
DRUG

Istradefylline

One 40 mg-tablet administered on Day 1

Trial Locations (2)

32908

Orlando Clinical Research Center, Orlando

37920

Noccr/Vrg, Knoxville

Sponsors
All Listed Sponsors
collaborator

Kyowa Hakko Kirin Pharma, Inc.

INDUSTRY

lead

Kyowa Kirin Co., Ltd.

INDUSTRY